Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:ALLO NASDAQ:INZY NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.27-0.5%$0.27$0.20▼$1.48$72.70M2.181.64 million shs519,720 shsALLOAllogene Therapeutics$1.26+4.1%$1.24$0.86▼$3.78$275.60M0.313.32 million shs8.08 million shsINZYInozyme Pharma$4.00$3.45$0.72▼$6.24$258.25M2.27932,836 shsN/ATNXPTonix Pharmaceuticals$42.36+10.4%$31.67$6.76▼$130.00$311.77M2.05963,517 shs1.03 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+9.01%+13.78%-2.09%+28.28%-77.02%ALLOAllogene Therapeutics+0.83%+0.83%-14.18%-11.68%-47.39%INZYInozyme Pharma0.00%0.00%+0.50%+354.18%-13.04%TNXPTonix Pharmaceuticals+7.87%+9.07%-2.14%+121.73%-36.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.1531 of 5 stars3.15.00.00.01.30.80.0ALLOAllogene Therapeutics3.0026 of 5 stars4.51.00.00.00.63.30.6INZYInozyme Pharma3.435 of 5 stars4.24.00.00.01.92.50.0TNXPTonix Pharmaceuticals2.5076 of 5 stars3.52.00.00.00.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.29Hold$1.35392.77% UpsideALLOAllogene Therapeutics 2.90Moderate Buy$8.44570.19% UpsideINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,281.02% UpsideCurrent Analyst Ratings BreakdownLatest ADAP, TNXP, ALLO, and INZY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.506/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.41N/AN/A$0.05 per share5.49ALLOAllogene TherapeuticsN/AN/AN/AN/A$2.01 per shareN/AINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ATNXPTonix Pharmaceuticals$10.09M30.90N/AN/A$31.82 per share1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)ALLOAllogene Therapeutics-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest ADAP, TNXP, ALLO, and INZY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025N/AALLOAllogene Therapeutics-$0.28N/AN/AN/AN/AN/A8/5/2025Q2 2025INZYInozyme Pharma-$0.36N/AN/AN/AN/AN/A5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics4.242.021.79ALLOAllogene TherapeuticsN/A9.719.71INZYInozyme Pharma0.652.192.19TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%ALLOAllogene Therapeutics83.63%INZYInozyme Pharma88.30%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%ALLOAllogene Therapeutics13.20%INZYInozyme Pharma12.18%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million231.28 millionOptionableALLOAllogene Therapeutics310218.73 million189.86 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableADAP, TNXP, ALLO, and INZY HeadlinesRecent News About These CompaniesTonix up after peer reviewed data for pain therapy and new data for mpox vaccineJuly 10 at 1:32 PM | msn.comTonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine ResultsJuly 10 at 1:32 PM | msn.comTonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data ReleaseJuly 10 at 1:13 PM | gurufocus.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?July 10 at 1:13 PM | marketbeat.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10 at 8:21 AM | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10 at 8:21 AM | gurufocus.comTonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock NewsJuly 10 at 8:21 AM | gurufocus.comTonix Pharma Unveils Promising TNX-801 Vaccine FindingsJuly 10 at 7:45 AM | tipranks.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025July 10 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's WhyJuly 9 at 5:39 PM | marketbeat.comTonix Pharma Publishes Phase 3 Trial ResultsJuly 9 at 5:17 PM | tipranks.comTonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia ManagementJuly 9 at 4:17 PM | quiverquant.comQTonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain MedicineJuly 9 at 4:01 PM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's WhyJuly 7 at 1:14 PM | marketbeat.comTonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against MonkeypoxJuly 7 at 7:24 AM | quiverquant.comQTonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025July 7 at 7:00 AM | globenewswire.comTNXP Tonix Pharmaceuticals Holding Corp. - Seeking AlphaJuly 4, 2025 | seekingalpha.comTonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer ModelsJuly 2, 2025 | quiverquant.comQTonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal ModelsJuly 2, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's WhyJuly 1, 2025 | marketbeat.comTonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexesJune 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes InvestorsThe Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesHSAs for Gym Memberships? These 3 Fitness Stocks Could SoarBy Chris Markoch | June 24, 2025View HSAs for Gym Memberships? These 3 Fitness Stocks Could SoarDave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYBy Thomas Hughes | June 11, 2025View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYADAP, TNXP, ALLO, and INZY Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.27 0.00 (-0.54%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.62%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Allogene Therapeutics NASDAQ:ALLO$1.26 +0.05 (+4.13%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.02 (+1.59%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Inozyme Pharma NASDAQ:INZY$4.00 0.00 (0.00%) As of 07/1/2025Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Tonix Pharmaceuticals NASDAQ:TNXP$42.36 +4.00 (+10.43%) Closing price 04:00 PM EasternExtended Trading$42.30 -0.06 (-0.15%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
